Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BLU-782 When Administered Orally to Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Fidrisertib (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Blueprint Medicines
- 06 Nov 2019 Status changed from recruiting to completed.
- 16 Oct 2019 According to a Blueprint Medicines media release, preliminary data were presented at the American Society of Bone and Mineral Research Annual Meeting in September 2019.
- 16 Oct 2019 Results presented in a Blueprint Medicines Media Release.